News & Updates

Adjuvant treatment with aspirin appears to provide some protection in patients with resected, PIK3CA-mutant stage II and III colon cancer, demonstrating a clinically significant improvement (43 percent) in disease-free survival (DFS), suggests a study presented at ESMO Congress 2024.

In the treatment of patients with pulmonary arterial hypertension, adding selexipag as a third medication sooner rather than later is crucial to help prevent hospitalization and disease progression, as suggested in an emulated target trial.